[Serum digoxin in children treated with beta methyl digoxin].
Concentrations of serum digoxin were measured by the polarized immunofluorescence Abbot TDx11 method in 59 samples from 53 children under treatment with mean beta methyl digoxin doses of 8.9 +/- 2.0 micrograms.kg.day. The therapeutic range for serum digoxin concentration was estimated to be 0.9 to 2.25 ng/ml. Simultaneous Na, K and creatine serum concentrations were measured. In 36 samples mean serum digoxin level was 1.52 +/- 0.45 ng/ml -within therapeutic range- and in only one of these cases clinical evidence of toxicity was apparent. In 15 samples digoxin level was above the therapeutic range and 11 patients of this group (73%) showed clinical signs of toxicity, consisting in arrythmias (six cases: supraventricular in 5 patients, ventricular in one child) and gastrointestinal symptoms (eight patients). Six patients with digoxin levels over therapeutic range and signs of digitalis toxicity had coincidental acute renal failure, which in 4 cases was subclinical--in 2 of these late it was pre-renal- and, in spite of this, all were inadvertently given the usual dosage of beta methyl digoxin. Almost invariably there was clinical evidence of toxicity when digoxin serum levels were above 2.4 ng/ml, so established maximal therapeutic level at 2.25 ng/ml seems adequate. Signs of digitalis toxicity must be looked on systematically in children treated with such drugs. In the critically ill or in children with acute renal failure it is necessary to monitor serum digoxin concentration. Among the clinical signs of toxicity, gastrointestinal symptoms are more frequent in children. An oral dose from 7 to 10 micrograms.kg.day of beta methyl digoxin in recommended.
Soler
P
P
Centro Cardiovascular, Hospital, Luis Calvo Mackenna.
García
Y
Y
Zilleruelo
R
R
Enríquez
G
G
Eimbcke
F
F
Vicuña
D
D
Jaeger
H
H
D058186:Acute Kidney Injury / Q000097:blood / Q000150:complications; D000367:Age Factors; D002318:Cardiovascular Diseases / Q000139:chemically induced / Q000175:diagnosis / Q000188:drug therapy*; D002648:Child; D002675:Child, Preschool; D004077:Digoxin / Q000009:adverse effects / Q000097:blood*; D016903:Drug Monitoring; D005260:Female; D005455:Fluorescent Antibody Technique; D005767:Gastrointestinal Diseases / Q000139:chemically induced; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D008297:Male; D008520:Medigoxin / Q000009:adverse effects* / Q000493:pharmacokinetics / Q000627:therapeutic use
D004077:Digoxin; D008520:Medigoxin
Concentraciones séricas de digoxina en niños tratados con beta metil digoxina.